Lyra Therapeutics (LYRA) Projected to Post Quarterly Earnings on Tuesday

Lyra Therapeutics (NASDAQ:LYRA) is expected to be announcing its Q1 2026 resultson Tuesday, May 12th. Analysts expect the company to announce earnings of ($1.36) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Lyra Therapeutics Stock Performance

Shares of NASDAQ LYRA traded down $0.02 during trading hours on Tuesday, hitting $0.73. The stock had a trading volume of 272 shares, compared to its average volume of 76,120. The company has a market capitalization of $1.30 million, a P/E ratio of -0.03 and a beta of 0.68. The firm’s 50-day moving average price is $0.82 and its two-hundred day moving average price is $2.59. Lyra Therapeutics has a 52 week low of $0.31 and a 52 week high of $37.50.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lyra Therapeutics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

Institutional Investors Weigh In On Lyra Therapeutics

Hedge funds have recently modified their holdings of the business. DRW Securities LLC bought a new stake in shares of Lyra Therapeutics in the fourth quarter valued at approximately $52,000. Citadel Advisors LLC bought a new stake in shares of Lyra Therapeutics in the third quarter valued at approximately $128,000. Finally, Bank of America Corp DE boosted its position in shares of Lyra Therapeutics by 33.7% in the second quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock valued at $256,000 after acquiring an additional 7,190 shares during the period. 95.62% of the stock is owned by institutional investors.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).